Heart Disease Trial, Recruiting NCT07230847 Sponsor: China National Center for Cardiovascular Diseases Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT07230847
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older

  • Men, or women who are not pregnant

  • People who have had an acute coronary syndrome (a sudden, serious heart condition such as a heart attack) and need a procedure called PCI, which opens blocked heart arteries using a small balloon and often a stent

  • People for whom heart bypass surgery (a different type of heart operation) is not ruled out

  • People considered to be at high risk of bleeding, based on a specific medical scoring system — this means meeting at least one "major" or two "minor" risk factors from the lists below:

    Major bleeding risk factors include:

    • Needing long-term blood thinning tablets
    • Severely reduced kidney function
    • Moderate to severe low red blood cell levels (anaemia)
    • A serious bleeding episode requiring a hospital stay or blood transfusion within the past 6 months, or repeated bleeding episodes
    • A long-term condition that causes abnormal bleeding
    • A very low platelet count (platelets help blood clot) before the procedure
    • Liver cirrhosis with high pressure in the liver's blood vessels
    • A diagnosis or treatment for cancer (other than certain skin cancers) in the past 12 months
    • A history of bleeding inside the brain that happened on its own
    • Bleeding inside the brain caused by injury within the past 12 months
    • A known abnormal tangle of blood vessels in the brain
    • A moderate to severe stroke caused by reduced blood flow within the past 6 months
    • Major surgery or serious physical trauma within the 30 days before the procedure
    • Major surgery that cannot be postponed, planned during the period when dual blood-thinning medication would be needed

    Minor bleeding risk factors include:

    • Age 75 or older
    • Mildly to moderately reduced kidney function
    • Mild anaemia (low red blood cell levels)
    • A serious bleeding episode requiring hospital care between 6 and 12 months before the procedure
    • Ongoing use of anti-inflammatory pain medicines (such as ibuprofen) or steroids after the procedure
    • A stroke caused by reduced blood flow that occurred more than 6 months before the procedure
  • People who are able to understand the goals of the trial and agree to participate by signing a consent form

Based on the heart artery images (angiographic criteria), people may also need to meet these conditions:

  • The main artery being treated must be a natural coronary artery (not a previously placed bypass graft)
  • The blockage in that artery must be significant enough to warrant treatment, either blocking 70% or more of the artery, or 50–70% with additional evidence of reduced blood flow to the heart
  • There must be at least one other artery with a blockage that also needs treatment
  • That additional blockage must be suitable for a planned, non-urgent procedure within one month

Who may not be able to join:

  • People showing signs of heart failure, including those with significantly reduced heart pumping function, or moderate-to-severe heart failure symptoms (confirm with trial site for specific classifications)
  • People in cardiogenic shock (when the heart is suddenly unable to pump enough blood to meet the body's needs)
  • People with known allergies or medical reasons to avoid aspirin, clopidogrel, ticagrelor, heparin, contrast dyes used during heart procedures, or materials used in drug-coated stents
  • People whose life expectancy is less than 12 months, or who may have difficulty attending follow-up appointments
  • People currently enrolled in another clinical drug or medical device trial that has not yet reached its main measurement point
  • People with a history of substance misuse, such as alcohol, cocaine, or heroin
  • People with serious heart rhythm problems (confirm with trial site for specific types)
  • People with other medical conditions that the trial doctors consider make participation unsuitable

Based on heart artery images, people may also not be eligible if:

  • The blockage is in the left main coronary artery (the main artery supplying the left side of the heart)
  • The blockage is in a previously placed bypass graft
  • There is a large blood clot visible in the artery being treated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13701387189

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
China National Center for Cardiovascular Diseases
Registry
ClinicalTrials.gov
Start date
10 December 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

OCT-Detected Neointimal Strut Coverage at 1-Month Post-Procedure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov